Access to anti-retroviral drugs, male in Iceland

Iceland: Access to anti-retroviral drugs, male was 89.0% in 2024. ▲ Rising

Latest (2024)
89.0%
Change on year
down 2.2%
World rank
17th
of 141 countries
All-time high
91.0%
in 2023
All-time low
27.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Iceland, 2000–2024

204060801002000201220242000: 27 %2001: 33 %2002: 38 %2003: 43 %2004: 46 %2005: 49 %2006: 51 %2007: 52 %2008: 55 %2009: 59 %2010: 61 %2011: 63 %2012: 64 %2013: 65 %2014: 65 %2015: 65 %2016: 66 %2017: 76 %2018: 79 %2019: 82 %2020: 85 %2021: 84 %2022: 83 %2023: 91 %2024: 89 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Iceland is 89.0%, measured in 2024.

Compared with earlier readings it is down 2.2% on the previous year and up 36.9% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Iceland peaked at 91.0% in 2023 and was at its lowest, 27.0%, in 2000.

Iceland ranks 17th of 141 countries on this measure, in the top quarter.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, male in Iceland, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Iceland, 2000 to 2024.
Year % Change
2000 27.0%
2001 33.0% +22.2%
2002 38.0% +15.2%
2003 43.0% +13.2%
2004 46.0% +7.0%
2005 49.0% +6.5%
2006 51.0% +4.1%
2007 52.0% +2.0%
2008 55.0% +5.8%
2009 59.0% +7.3%
2010 61.0% +3.4%
2011 63.0% +3.3%
2012 64.0% +1.6%
2013 65.0% +1.6%
2014 65.0% +0.0%
2015 65.0% +0.0%
2016 66.0% +1.5%
2017 76.0% +15.2%
2018 79.0% +3.9%
2019 82.0% +3.8%
2020 85.0% +3.7%
2021 84.0% -1.2%
2022 83.0% -1.2%
2023 91.0% +9.6%
2024 89.0% -2.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 45.3% 27.0% 59.0% 10
2010s 68.6% 61.0% 82.0% 10
2020s 86.4% 83.0% 91.0% 5

Countries ranked near Iceland

  1. 17 France 89.0% compare
  2. 17 Ireland 89.0% compare
  3. 17 Netherlands 89.0% compare
  4. 17 Romania 89.0% compare
  5. 17 Zimbabwe 89.0% compare

See the full ranking of 160 places →

More gender data for Iceland

All data for Iceland →

Frequently asked questions

What is access to anti-retroviral drugs, male in Iceland?
Access to anti-retroviral drugs, male in Iceland was 89.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Iceland?
The highest recorded value was 91.0% in 2023.
What is the lowest access to anti-retroviral drugs, male recorded in Iceland?
The lowest recorded value was 27.0% in 2000.
How does Iceland rank for access to anti-retroviral drugs, male?
Iceland ranks 17th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Iceland?
Over the last ten years it is up 36.9%. The long-run trend across the full record is rising.
Where does this Iceland data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Iceland. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/iceland/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/iceland/">Access to anti-retroviral drugs, male in Iceland</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.